Enzymatica strengthens its Board with competency and experience from the pharmaceutical industry. Anders Jungbeck, vice president of the international pharmaceutical company Actavis, has been proposed as new member of the Board of Enzymatica. Anders Jungbeck has the past 29 years been working in both the Swedish and international pharmaceutical industry in companies as Glaxo, Draco, AstraZeneca and Ratiopharm.
- We are very pleased to have Anders Jungbeck to candidate for our Board. By having Anders on the Board we get a good gain in terms of experience from the international pharmaceutical market place, which is especially important in connection with our planned expansion in the Nordic region and Europe, says Michael Edelborg Christensen, CEO of Enzymatica.
- It feels really exhilarating to be proposed as a member of Enzymatica. It is a very interesting biotech company with an exciting pipeline of products, says Anders Jungbeck.
For more information on Enzymatica, contact:
Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against periodontal diseases and ColdZyme Mouth Spray against common cold recently launched in pharmacies throughout the country.